Article
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Nature medicine - 1 Mar 2023
van de Haar Joris, Ma Xuhui, Ooft Salo N, van der Helm Pim W, Hoes Louisa R, Mainardi Sara, Pinato David J, Sun Kristi, Salvatore Lisa, Tortora Giampaolo, Zurlo Ina Valeria, Leo Silvana, Giampieri Riccardo, Berardi Rossana, Gelsomino Fabio, Merz Valeria, Mazzuca Federica, Antonuzzo Lorenzo, Rosati Gerardo, Stavraka Chara, Ross Paul, Rodriquenz Maria Grazia, Pavarana Michele, Messina Carlo, Iveson Timothy, Zoratto Federica, Thomas Anne, Fenocchio Elisabetta, Ratti Margherita, Depetris Ilaria, Cergnul Massimiliano, Morelli Cristina, Libertini Michela, Parisi Alessandro, De Tursi Michele, Zanaletti Nicoletta, Garrone Ornella, Graham Janet, Longarini Raffaella, Gobba Stefania Maria, Petrillo Angelica, Tamburini Emiliano, La Verde Nicla, Petrelli Fausto, Ricci Vincenzo, Wessels Lodewyk F A, Ghidini Michele, Cortellini Alessio, Voest Emile E, Valeri Nicola
Abstract excerpt
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified KRAS codon G12 (KRASG12) mutations as a potential biomarker of resistance. Next, we collected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.